Source: MVS Noticias
The company Sanofi Aventis filed a complaint for counterfeiting of the Plaquenil product.
The Federal Commission for the Protection against Sanitary Risks (Cofepris) issued a health alert for the counterfeiting of the drug hydroxychloroquine, marketed under the name Plaquenil.
In a statement, he explained that the company Sanofi Aventis filed a complaint for the falsification of the product Plaquenil in its presentation of 200 milligram tablets and warned that this product does not contain the active ingredient hydroxychloroquine , instead microcrystalline cellulose was identified , and the box There are differences in the printing of the price, the font used in the texts and the color.
Related:
Mexico to administer hydroxychloroquine to 20,000
How a False Hydroxychloroquine Narrative Was Created. “Dangerous” When Used for Covid-19
National Cancer Instititute: List of Active Clinical Trials Using Hydroxychloroquine for Cancer